BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26:153-161. [PMID: 16673293 DOI: 10.1055/s-2006-939753] [Cited by in Crossref: 165] [Cited by in F6Publishing: 165] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
2 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
3 Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108. [PMID: 21933440 DOI: 10.1186/1477-7819-9-108] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
4 Wong VW, Wong GL, Chim AM, Choi PC, Chan AW, Tsang SW, Hui AY, Chan H, Sung JJ, Chan HL. Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2009;7:1113-20. [DOI: 10.1016/j.cgh.2009.05.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
5 Chen H, Sun J, Zhou B, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clin Gastroenterol Hepatol 2020;18:196-204.e8. [PMID: 31042581 DOI: 10.1016/j.cgh.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Chen X, Zhang L, Chang Y, Shen T, Wang L, Zhuang H, Lu F. Association of TNF-alpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han Chinese population. Int J Biol Markers. 2011;26:181-187. [PMID: 21928250 DOI: 10.5301/jbm.2011.8580] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
7 Li F, Li X, Yan T, Liu Y, Cheng Y, Xu Z, Shao Q, Liao H, Huang P, Li J, Chen GF, Xu D. The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection. Hepatol Int 2018;12:107-17. [PMID: 29651701 DOI: 10.1007/s12072-018-9858-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int. 2012;32:271-278. [PMID: 22098536 DOI: 10.1111/j.1478-3231.2011.02634.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
9 Wong VW, Wong GL, Yan KK, Chim AM, Chan H, Tse C, Choi PC, Chan AW, Sung JJ, Chan HL. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-53. [DOI: 10.1002/hep.23568] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 6.6] [Reference Citation Analysis]
10 Kim NH, Cho YK, Kim BI, Kim HJ. Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment. Dig Dis Sci 2018;63:2792-9. [PMID: 29948568 DOI: 10.1007/s10620-018-5165-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
11 Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1059-1068. [PMID: 20807216 DOI: 10.1111/j.1365-2036.2010.04447.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323-1331. [PMID: 21050234 DOI: 10.1111/j.1365-2036.2010.04474.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
13 Chan HL. JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol. 2011;26:8-12. [PMID: 21175787 DOI: 10.1111/j.1440-1746.2010.06514.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
14 Zhang L, Gong F, Zhang F, Ma J, Zhang P, Shen J. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine. 2013;8:1517-1524. [PMID: 23620667 DOI: 10.2147/ijn.s43263] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
15 Qu LS, Liu JX, Kuai XL, Xu ZF, Jin F, Zhou GX. Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis. Hepatol Res 2014;44:750-60. [PMID: 23710537 DOI: 10.1111/hepr.12172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
16 El Hadad S, Alakilli S, Rabah S, Sabir J. Sequence analysis of sub-genotype D hepatitis B surface antigens isolated from Jeddah, Saudi Arabia. Saudi J Biol Sci 2018;25:838-47. [PMID: 29740253 DOI: 10.1016/j.sjbs.2016.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Liu YY, Li CP, Huai MS, Fu XM, Cui Z, Fan LL, Zhang S, Liu Y, Ma J, Li G. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression. PLoS One. 2015;10:e0120939. [PMID: 25816221 DOI: 10.1371/journal.pone.0120939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
18 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
19 Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177-182. [PMID: 18182659 DOI: 10.1200/jco.2007.13.2043] [Cited by in Crossref: 207] [Cited by in F6Publishing: 81] [Article Influence: 14.8] [Reference Citation Analysis]
20 Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med 2014;8:135-44. [PMID: 24810645 DOI: 10.1007/s11684-014-0331-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
21 Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013;33:595-604. [PMID: 23402625 DOI: 10.1111/liv.12112] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
22 Yu SJ. Regression of liver cirrhosis: orthodoxy or paradigm shift? Clin Mol Hepatol 2015;21:22-3. [PMID: 25834798 DOI: 10.3350/cmh.2015.21.1.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Sheng Y, Ding S, Chen K, Chen J, Wang S, Zou C, Zhang J, Cao Y, Huang A, Tang H. Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Biochem Cell Biol 2014;92:152-62. [PMID: 24697700 DOI: 10.1139/bcb-2013-0128] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
24 Domagalski K, Pawłowska M, Zaleśna A, Tyczyno M, Skorupa-Kłaput M, Tretyn A, Halota W. The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Microbiol Infect Dis 2014;33:2025-33. [PMID: 24924923 DOI: 10.1007/s10096-014-2172-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
26 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rushbrook SM, Hoare M, Alexander GJ. T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther 2007;7:1689-703. [PMID: 17961092 DOI: 10.1517/14712598.7.11.1689] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
28 Yang Y, Yuan S, Zhao L, Wang C, Ni J, Wang Z, Lin C, Wu M, Zhou W. Ligand-Directed Stearic Acid Grafted Chitosan Micelles to Increase Therapeutic Efficacy in Hepatic Cancer. Mol Pharmaceutics 2015;12:644-52. [DOI: 10.1021/mp500723k] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
29 Chan HL, Wong GL, Tse CH, Chim AM, Yiu KK, Chan HY, Sung JJ, Wong VW. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol. 2009;7:1361-1366. [PMID: 19683072 DOI: 10.1016/j.cgh.2009.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
30 Panjaworayan N, Roessner SK, Firth AE, Brown CM. HBVRegDB: annotation, comparison, detection and visualization of regulatory elements in hepatitis B virus sequences. Virol J 2007;4:136. [PMID: 18086305 DOI: 10.1186/1743-422X-4-136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kim JK, Chang HY, Lee JM, Baatarkhuu O, Yoon YJ, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol. 2009;81:1002-1008. [PMID: 19382267 DOI: 10.1002/jmv.21501] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
32 Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-2770. [PMID: 19267406 DOI: 10.1002/ijc.24281] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 10.4] [Reference Citation Analysis]
33 Wong GLH. Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol 2015; 7(18): 2133-2135 [PMID: 26328024 DOI: 10.4254/wjh.v7.i18.2133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
35 Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 2009; 15(44): 5592-5597 [PMID: 19938200 DOI: 10.3748/wjg.15.5592] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
36 Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50:990-998. [PMID: 19303657 DOI: 10.1016/j.jhep.2008.12.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
37 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
38 Yang JQ, Pan GD, Chu GP, Liu Z, Liu Q, Xiao Y, Yuan L. Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol 2008; 14(36): 5564-5569 [PMID: 18810776 DOI: 10.3748/wjg.14.5564] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
39 Yen C, Ai Y, Tsai H, Chan S, Yen C, Cheng K, Lee Y, Kao C, Wang Y, Chen Y, Lin C, Liu T, Tsai H, Wang J, Su I, Huang W. Hepatitis B virus surface gene pre-S 2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology 2018;68:815-26. [DOI: 10.1002/hep.29790] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
40 Schittl B, Bruss V. Mutational profiling of the variability of individual amino acid positions in the hepatitis B virus matrix domain. Virology 2014;458-459:183-9. [PMID: 24928050 DOI: 10.1016/j.virol.2014.04.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34:972-981. [PMID: 21883327 DOI: 10.1111/j.1365-2036.2011.04833.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
42 Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52:1232-1241. [PMID: 20648555 DOI: 10.1002/hep.23803] [Cited by in Crossref: 177] [Cited by in F6Publishing: 163] [Article Influence: 14.8] [Reference Citation Analysis]
43 Zhang Y, Zhang B, Zhang A, Li X, Liu J, Zhao J, Zhao Y, Gao J, Fang D, Rao Z. IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells. Braz J Med Biol Res 2013;46:32-8. [PMID: 23011405 DOI: 10.1590/s0100-879x2012007500155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
44 Wang X, Wang Q, Lin H, Li S, Sun L, Yang Y. HSP72 and gp96 in gastroenterological cancers. Clin Chim Acta 2013;417:73-9. [PMID: 23266770 DOI: 10.1016/j.cca.2012.12.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
45 Ding W, Mouzaki M, You H, Laird JC, Mato J, Lu SC, Rountree CB. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology. 2009;49:1277-1286. [PMID: 19115422 DOI: 10.1002/hep.22743] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 5.4] [Reference Citation Analysis]
46 Cheng JY, Wong VW, Tse Y, Chim AM, Chan HL, Wong GL. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B: Cheng et al. Hepatology 2016;64:1507-17. [DOI: 10.1002/hep.28778] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
47 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2009;7:227-233. [PMID: 19121647 DOI: 10.1016/j.cgh.2008.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
48 Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326-1335. [PMID: 22506552 DOI: 10.1111/j.1365-2036.2012.05098.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
49 Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. Gastroenterology 2012;142:513-520.e1. [DOI: 10.1053/j.gastro.2011.11.025] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 11.7] [Reference Citation Analysis]
50 Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016; 22(4): 1461-1476 [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 56] [Article Influence: 11.0] [Reference Citation Analysis]
51 Wai-sun Wong V, Lik-yuen Chan H. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology 2012;11:284-93. [DOI: 10.1016/s1665-2681(19)30922-6] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
52 Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, Liu Y, Shi L, Song G, Yang Y. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int 2012;32:1172-8. [DOI: 10.1111/j.1478-3231.2012.02787.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
53 Chan HL, Wong VW, Wong GL, Chim AM, Lai LH, Sung JJ. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 2009;47:1830-6. [PMID: 19386857 DOI: 10.1128/JCM.00029-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
54 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
55 Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol 2013;34:1451-9. [PMID: 23564481 DOI: 10.1007/s13277-013-0649-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
56 Wang MD, Li C, Liang L, Xing H, Sun LY, Quan B, Wu H, Xu XF, Wu MC, Pawlik TM, Lau WY, Shen F, Yang T. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist 2020;25:e1541-51. [PMID: 32472951 DOI: 10.1634/theoncologist.2019-0944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
57 Wong GL, Chan HL, Yu Z, Wong CK, Leung C, Ho PP, Chan CY, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Chan HY, Tse CH, Wong VW. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30:582-90. [PMID: 25252074 DOI: 10.1111/jgh.12779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
58 Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872-80. [PMID: 23553752 DOI: 10.1002/hep.26436] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
59 Zhang X, Zhang W, Ye L. Pathogenesis of hepatitis B virus infection. Future Virology 2006;1:637-47. [DOI: 10.2217/17460794.1.5.637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lee JM, Seo YS, Kim TH, Ahn JM, Yim SY, Kim SU, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS. The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:208-14. [PMID: 27194632 DOI: 10.1111/jgh.13447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
61 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan H, Sung JJ, Chan HL. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2011;54:236-42. [DOI: 10.1016/j.jhep.2010.06.043] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
62 Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969. [PMID: 27446846 DOI: 10.1155/2016/5234969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
63 Cheung YS, Chan HL, Wong J, Lee KF, Poon TC, Wong N, Lai PB. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31:41-49. [PMID: 18490213 DOI: 10.1016/s1015-9584(08)60056-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
64 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
65 Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK. Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol. 2008;82:3604-3611. [PMID: 18216102 DOI: 10.1128/jvi.01197-07] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wang C, Teng Z, Zhu Y, Zhao AZ, Sun C. Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis. Med Sci Monit. 2015;21:1072-1077. [PMID: 25868851 DOI: 10.12659/msm.894058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
67 Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis. 2011;32:1122-1132. [PMID: 21665892 DOI: 10.1093/carcin/bgr108] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
68 Yang Y, Lu Q, Shao X, Mo B, Nie X, Liu W, Chen X, Tang Y, Deng Y, Yan J. Development Of A Three-Gene Prognostic Signature For Hepatitis B Virus Associated Hepatocellular Carcinoma Based On Integrated Transcriptomic Analysis. J Cancer 2018;9:1989-2002. [PMID: 29896284 DOI: 10.7150/jca.23762] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
69 Seitz S, Urban S, Antoni C, Böttcher B. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J. 2007;26:4160-4167. [PMID: 17762862 DOI: 10.1038/sj.emboj.7601841] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
70 Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2012;57:221-231. [PMID: 21743991 DOI: 10.1007/s10620-011-1816-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
71 Wang J, Pu Y, Gong Y, Li Z, Zhu X. A statistical analysis of the correlations among various types of clinical indexes for patients with chronic hepatitis B: A hospital-based study. Medicine (Baltimore) 2020;99:e19201. [PMID: 32080106 DOI: 10.1097/MD.0000000000019201] [Reference Citation Analysis]
72 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan H, Chan FK, Sung JJ, Chan HL. Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. The American Journal of Gastroenterology 2008;103:3071-81. [DOI: 10.1111/j.1572-0241.2008.02157.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
73 Zao X, Cheng J, Shen C, Guan G, Feng X, Zou J, Zhang J, Liu T, Zheng H, Zhang T, Wang J, Liu J, Li D, Lu F, You F, Chen X. NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription. Oncoimmunology 2021;10:1869388. [PMID: 33520407 DOI: 10.1080/2162402X.2020.1869388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Liu H, Shi W, Luan F, Xu S, Yang F, Sun W, Liu J, Ma C. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes. 2010;40:174-182. [PMID: 20107884 DOI: 10.1007/s11262-009-0441-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
75 Kondo Y, Ninomiya M, Kakazu E, Kimura O, Shimosegawa T. Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection. ISRN Gastroenterol. 2013;2013:935295. [PMID: 23401786 DOI: 10.1155/2013/935295] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
76 Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007; 13(1): 74-81 [PMID: 17206756 DOI: 10.3748/wjg.v13.i1.74] [Cited by in CrossRef: 170] [Cited by in F6Publishing: 167] [Article Influence: 11.3] [Reference Citation Analysis]
77 Ha HL, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol 2010; 16(48): 6035-6043 [PMID: 21182217 DOI: 10.3748/wjg.v16.i48.6035] [Cited by in CrossRef: 139] [Cited by in F6Publishing: 128] [Article Influence: 11.6] [Reference Citation Analysis]
78 Mao Q, Zhang HY, You JP, Zhang XQ. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid. Virol J 2012;9:136. [PMID: 22828242 DOI: 10.1186/1743-422X-9-136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
79 Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408-414. [PMID: 21742839 DOI: 10.1093/infdis/jir283] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
80 Wong VW, Chan SL, Mo F, Chan T, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. JCO 2010;28:1660-5. [DOI: 10.1200/jco.2009.26.2675] [Cited by in Crossref: 290] [Cited by in F6Publishing: 106] [Article Influence: 24.2] [Reference Citation Analysis]
81 Zhu R, Zhang HP, Yu H, Li H, Ling YQ, Hu XQ, Zhu HG. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients. Pathol Res Pract 2008;204:731-42. [PMID: 18597951 DOI: 10.1016/j.prp.2008.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
82 Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opinion on Drug Metabolism & Toxicology 2008;4:1351-61. [DOI: 10.1517/17425255.4.10.1351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
83 Ong A, Wong VW, Wong GL, Chan HL. The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int. 2011;31:1047-1053. [PMID: 21733095 DOI: 10.1111/j.1478-3231.2011.02555.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
84 Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59:986-995. [PMID: 24123097 DOI: 10.1002/hep.26739] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
85 Wong VW, Sung JJ. Antiviral therapy for chronic hepatitis B: are we doing any good to patients? J Antimicrob Chemother 2009;64:223-6. [PMID: 19468026 DOI: 10.1093/jac/dkp189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 8.3] [Reference Citation Analysis]
87 Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 2014;110:733-40. [PMID: 24495874 DOI: 10.1038/bjc.2013.781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
88 Rybicka M, Woziwodzka A, Romanowski T, Sznarkowska A, Stalke P, Dręczewski M, Bielawski KP. Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B. J Clin Virol 2019;120:1-5. [PMID: 31505315 DOI: 10.1016/j.jcv.2019.09.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Peng Q, Lao X, Chen Z, Lai H, Deng Y, Wang J, Mo C, Sui J, Wu J, Zhai L. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2013;8:e82773. [PMID: 24376578 DOI: 10.1371/journal.pone.0082773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
90 Wang LH, Huang W, Lai MD, Su IJ. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis. 2012;33:466-472. [PMID: 22159224 DOI: 10.1093/carcin/bgr296] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
91 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774-780. [PMID: 21294143 DOI: 10.1002/hep.24109] [Cited by in Crossref: 167] [Cited by in F6Publishing: 150] [Article Influence: 15.2] [Reference Citation Analysis]
92 Itokawa N, Atsukawa M, Tsubota A, Shimada N, Toyoda H, Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K. Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B. Intern Med 2021;60:507-16. [PMID: 33583931 DOI: 10.2169/internalmedicine.5432-20] [Reference Citation Analysis]
93 Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, Manolakopoulos S, Pectasides D. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014;25:768-771. [PMID: 25037900 DOI: 10.1016/j.ejim.2014.06.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
95 Qu LS, Zhu J, Liu TT, Shen XZ, Chen TY, Ni ZP, Ni RZ, Lu CH. Effect of combined mutations in the enhancer II and basal core promoter of hepatitis B virus on development of hepatocellular carcinoma in Qidong, China. Hepatol Res. 2014;44:1186-1195. [PMID: 24341484 DOI: 10.1111/hepr.12291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
96 Chan HL, Wong VW, Wong GL, Chim AM, Chan H, Sung JJ. Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. Clinical Gastroenterology and Hepatology 2008;6:1022-6. [DOI: 10.1016/j.cgh.2008.03.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
97 Abdelbaky SB, Ibrahim MT, Samy H, Mohamed M, Mohamed H, Mustafa M, Abdelaziz MM, Forrest ML, Khalil IA. Cancer immunotherapy from biology to nanomedicine. J Control Release 2021;336:410-32. [PMID: 34171445 DOI: 10.1016/j.jconrel.2021.06.025] [Reference Citation Analysis]
98 Ying SY, Hu YR, Gao GS, Lou KH, Huang Z. Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. Front Med (Lausanne) 2021;8:691365. [PMID: 34307418 DOI: 10.3389/fmed.2021.691365] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W, Yu SC. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 2014;16:366-372. [PMID: 23980880 DOI: 10.1111/hpb.12146] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
100 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008;48:335-52. [DOI: 10.1016/j.jhep.2007.11.011] [Cited by in Crossref: 791] [Cited by in F6Publishing: 748] [Article Influence: 56.5] [Reference Citation Analysis]
101 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
102 Zhou ZG, Zheng XR, Zhou Q, Shi M, Zhang YJ, Guo RP, Yuan YF, Chen MS, Lin XJ, Lao XM, Li SP. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chin J Cancer 2015;34:205-16. [PMID: 26058595 DOI: 10.1186/s40880-015-0017-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
103 Wong GL, Kwok R, Chan HL, Tang SP, Lee E, Lam TC, Lau TW, Ma TM, Wong BC, Wong VW. Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. J Dig Dis. 2016;17:538-546. [PMID: 27185358 DOI: 10.1111/1751-2980.12359] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
104 Kiyici M, Yilmaz M, Akyildiz M, Arikan C, Aydin U, Sigirli D, Nart D, Yilmaz F, Ozacar T, Karasu Z, Kilic M. Association Between Hepatitis B and Hepatocellular Carcinoma Recurrence in Patients Undergoing Liver Transplantation. Transplantation Proceedings 2008;40:1511-7. [DOI: 10.1016/j.transproceed.2008.03.156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
105 Wong GL. Who will have the best response to entecavir? J Gastroenterol Hepatol 2013;28:5-7. [DOI: 10.1111/jgh.12009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
106 Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, Tse CH, Wong VW. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883-893. [PMID: 24612251 DOI: 10.1111/apt.12658] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 8.9] [Reference Citation Analysis]
107 Li T, Zhao XP, Wang LY, Gao S, Zhao J, Fan YC, Wang K. Glutathione S-transferase P1 correlated with oxidative stress in hepatocellular carcinoma. Int J Med Sci. 2013;10:683-690. [PMID: 23569432 DOI: 10.7150/ijms.5947] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
108 Li X, Wang Y, Han D, Zhang W, Zhang Z, Ye X, Tian L, Dong Y, Zhu Q, Chen Y. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B: HBsAg level and telbivudine treatment efficacy. Hepatol Res 2014;44:187-93. [DOI: 10.1111/hepr.12105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
109 Hsu A, Lai CL, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep. 2011;10:106-111. [PMID: 21654908 DOI: 10.1007/s11901-011-0094-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong C, Wong J, Lee K, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma: Meta-analysis: anti-viral therapy and HCC recurrence. Alimentary Pharmacology & Therapeutics 2011;33:1104-12. [DOI: 10.1111/j.1365-2036.2011.04634.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 10.5] [Reference Citation Analysis]
111 Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol. 2013;87:7977-7991. [PMID: 23678176 DOI: 10.1128/jvi.03540-12] [Cited by in Crossref: 114] [Cited by in F6Publishing: 64] [Article Influence: 12.7] [Reference Citation Analysis]
112 Zaky S, Farghaly AM, Rashed H, Hassan H, Faouzy E, Makhlouf N, Hussein MRA. Clinicopathologic features and genotyping of patients with chronic HBV infection in the Upper Egypt. Cellular Immunology 2010;265:97-104. [DOI: 10.1016/j.cellimm.2010.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
113 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608-620. [PMID: 23701455 DOI: 10.1111/hepr.12169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
114 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
115 Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, Cheung KK, Wong EW, Wong VW. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:517-526. [PMID: 23305043 DOI: 10.1111/apt.12207] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
116 Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis: TREATMENT OF IMMUNE TOLERANT HBV. Alimentary Pharmacology & Therapeutics 2007;26:383-91. [DOI: 10.1111/j.1365-2036.2007.03382.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
117 Zhou HY, Luo Y, Chen WD, Gong GZ. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis. J Gastroenterol Hepatol. 2015;30:977-983. [PMID: 25689418 DOI: 10.1111/jgh.12917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
118 Cheng B, Zheng Y, Guo X, Wang Y, Liu C. Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cells. Liver Int. 2010;30:319-326. [PMID: 19968784 DOI: 10.1111/j.1478-3231.2009.02167.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
119 Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY, Han K. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29:1192-6. [DOI: 10.1093/carcin/bgn090] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 6.6] [Reference Citation Analysis]
120 Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML, Wang SN. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 2010;24:195-200. [PMID: 20486202 DOI: 10.1002/jcla.20320] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
121 Zhang B, Xu D, Wang R, Zhu P, Mei B, Wei G, Xiao H, Zhang B, Chen X. Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. International Journal of Surgery 2015;15:1-5. [DOI: 10.1016/j.ijsu.2014.12.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok J, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41. [DOI: 10.1038/nbt1389] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 20.6] [Reference Citation Analysis]
123 Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111-1120. [PMID: 20422305 DOI: 10.1007/s11605-010-1211-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
124 Cheng P, Chiu Y, Tsai H, Wang R, Chiu H, Wu I, Chang T. HBsAg expression of liver correlates with histological activities and viral replication in chronic hepatitis B. Annals of Hepatology 2014;13:771-80. [DOI: 10.1016/s1665-2681(19)30979-2] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
125 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
126 Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther. 2014;40:716-726. [PMID: 25039861 DOI: 10.1111/apt.12874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
127 Yim SY, Lee JH, Ahn H, Kim SU, Kim SG, Kim YS, Kim JH, Choe WH, Kim TY, Jung YK, Suh SJ, Suk KT, An H, Yim HJ, Seo YS, Um SH. Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals. J Clin Gastroenterol 2016;50:676-85. [PMID: 27203430 DOI: 10.1097/MCG.0000000000000529] [Reference Citation Analysis]
128 Buhlmann S, Racek T, Schwarz A, Schaefer S, Pützer BM. Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. J Mol Biol. 2008;378:20-30. [PMID: 18342333 DOI: 10.1016/j.jmb.2008.02.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
129 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213-1218. [PMID: 24179497 DOI: 10.3892/ol.2013.1578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
130 Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. J Gastroenterol Hepatol. 2015;30:1237-1245. [PMID: 25708186 DOI: 10.1111/jgh.12934] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
131 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
132 Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol 2015;30:1024-31. [PMID: 25611175 DOI: 10.1111/jgh.12898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
133 Wong GL, Chan HL, Chan HY, Tse CH, Chim AM, Lo AO, Wong VW. Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2015;13:783-790.e1. [PMID: 25445773 DOI: 10.1016/j.cgh.2014.09.050] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
134 Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol. 2013;28:861-866. [PMID: 23301835 DOI: 10.1111/jgh.12110] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
135 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 7.3] [Reference Citation Analysis]
136 Wong GL, Tse Y, Chan HL, Yip TC, Tsoi KK, Wong VW. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2016;43:802-13. [DOI: 10.1111/apt.13548] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
137 Robotin MC. Hepatitis B prevention and control: Lessons from the East and the West. World J Hepatol 2011; 3(2): 31-37 [PMID: 21423912 DOI: 10.4254/wjh.v3.i2.31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
138 Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence. Journal of Hepatology 2009;51:842-4. [DOI: 10.1016/j.jhep.2009.08.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
139 Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933-944. [PMID: 23415803 DOI: 10.1053/j.gastro.2013.02.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 13.3] [Reference Citation Analysis]
140 Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol. 2013;57:323-330. [PMID: 23731848 DOI: 10.1016/j.jcv.2013.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
141 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
142 Wang X, Zhou Y, Sun L, Chen W, Li X, Wang Q, Lin H. Complex Formation between Heat Shock Protein 72 and Hepatitis B Virus X Protein in Hepatocellular Carcinoma Tissues. J Proteome Res 2008;7:5133-7. [DOI: 10.1021/pr800435g] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
143 Liu W, Cao Y, Wang T, Xiang G, Lu J, Zhang J, Hou P. The N-Glycosylation Modification of LHBs (Large Surface Proteins of HBV) Effects on Endoplasmic Reticulum Stress, Cell Proliferation and its Secretion. Hepat Mon. 2013;13:e12280. [PMID: 24282423 DOI: 10.5812/hepatmon.12280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
144 Yip WK, Cheng AS, Zhu R, Lung RW, Tsang DP, Lau SS, Chen Y, Sung JG, Lai PB, Ng EK, Yu J, Wong N, To KF, Wong VW, Sung JJ, Chan HL. Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. PLoS One. 2011;6:e22888. [PMID: 21829663 DOI: 10.1371/journal.pone.0022888] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
145 Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther. 2013;37:243-251. [PMID: 23171385 DOI: 10.1111/apt.12144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
146 Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339-345. [PMID: 24128413 DOI: 10.1016/j.jhep.2013.09.029] [Cited by in Crossref: 155] [Cited by in F6Publishing: 130] [Article Influence: 17.2] [Reference Citation Analysis]
147 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
148 Hu B, Wang R, Fu J, Su M, Du M, Liu Y, Li H, Wang H, Lu F, Jiang J. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. J Gastroenterol Hepatol 2018;33:1389-96. [PMID: 29266382 DOI: 10.1111/jgh.14075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
149 Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, Chan HY, Wong VW. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014;39:197-208. [PMID: 24261924 DOI: 10.1111/apt.12559] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
150 Shieh YS, Chang YS, Hong JR, Chen LJ, Jou LK, Hsu CC, Her GM. Increase of hepatic fat accumulation by liver specific expression of Hepatitis B virus X protein in zebrafish. Biochim Biophys Acta. 2010;1801:721-730. [PMID: 20416398 DOI: 10.1016/j.bbalip.2010.04.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
151 Cheng L, Sun X, Tan S, Tan W, Dan Y, Zhou Y, Mao Q, Deng G. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res. 2014;44:1000-1007. [PMID: 24298935 DOI: 10.1111/hepr.12284] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
152 Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, Wu Q, He Q, Tang X, Jiang R, Zhou F, Chen Y, Wen W, Chen J, Hou J. Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B. Liver Int 2019;39:1428-36. [PMID: 30920714 DOI: 10.1111/liv.14108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
153 Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y, Go MY, Yu DY, Cheung YS, Lai PB. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut. 2014;63:1793-1804. [PMID: 24440987 DOI: 10.1136/gutjnl-2013-305584] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
154 Lee MH, Kim do Y, Kim JK, Chang HY, Kang SH, Ryu HJ, Ju HL, Kim SU, Lee JM, Park JY. Combination of preS deletions and A1762T/G1764A mutations in HBV subgenotype C2 increases the risk of developing HCC. Intervirology. 2012;55:296-302. [PMID: 21865669 DOI: 10.1159/000329941] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
155 Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533-540. [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 12.5] [Reference Citation Analysis]
156 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547. [PMID: 23389810 DOI: 10.1002/hep.26301] [Cited by in Crossref: 295] [Cited by in F6Publishing: 283] [Article Influence: 32.8] [Reference Citation Analysis]
157 Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J Gastroenterol 2014; 20(28): 9229-9236 [PMID: 25071315 DOI: 10.3748/wjg.v20.i28.9229] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
158 Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, Cheng AS, Chim AM, Chan FK. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol. 2010;105:132-138. [PMID: 19809411 DOI: 10.1038/ajg.2009.560] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
159 Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38:683-691. [PMID: 22621971 DOI: 10.1016/j.ejso.2012.04.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
160 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
161 Chen Z, Chen J, Huang X, Wu Y, Huang K, Xu W, Xie L, Zhang X, Liu H. Identification of Potential Key Genes for Hepatitis B Virus-Associated Hepatocellular Carcinoma by Bioinformatics Analysis. J Comput Biol 2019;26:485-94. [PMID: 30864827 DOI: 10.1089/cmb.2018.0244] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
162 Lee HW. [Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma]. Korean J Gastroenterol 2019;74:251-7. [PMID: 31765553 DOI: 10.4166/kjg.2019.74.5.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Yu SJ, Lee JH, Jang ES, Cho EJ, Kwak MS, Yoon JH, Lee HS, Kim CY, Kim YJ. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology. 2013;267:638-647. [PMID: 23440326 DOI: 10.1148/radiol.13121498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
164 Schleiss MR, Patterson JC. Viral Infections of the Fetus and Newborn and Human Immunodeficiency Virus Infection during Pregnancy. Avery's Diseases of the Newborn. Elsevier; 2012. pp. 468-512. [DOI: 10.1016/b978-1-4377-0134-0.10037-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Wong GL. How does hepatitis B virus infection react to hepatocellular carcinoma treatment? J Gastroenterol Hepatol. 2012;27:1-2. [PMID: 22188022 DOI: 10.1111/j.1440-1746.2011.06950.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]